epirubicin has been researched along with Carcinoma, Non-Small Cell Lung in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (9.09) | 18.7374 |
| 1990's | 36 (46.75) | 18.2507 |
| 2000's | 22 (28.57) | 29.6817 |
| 2010's | 9 (11.69) | 24.3611 |
| 2020's | 3 (3.90) | 2.80 |
| Authors | Studies |
|---|---|
| Altuntas, S | 1 |
| Cai, FY; Fu, M; He, SY; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Liu, XZ; Yao, XM; Zhang, L | 1 |
| Hou, E; Lai, L; Lu, Y; Meng, W; Tan, Z; Wei, J; Zhang, X | 1 |
| An, L; Chu, HX; Fan, YH; Feng, F; Li, DD; Ma, HD; Song, Q; Wang, CL; Zhang, Q; Zhao, QC | 1 |
| Cheng, L; Fu, M; Gu, LY; Ju, RJ; Li, XT; Liu, JJ; Liu, S; Song, XL; Wang, X; Xiao, Y | 1 |
| Fan, J; Qiao, B; Zhang, W | 1 |
| Cai, FY; Fu, M; Gong, XQ; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Tang, W; Yao, XM | 1 |
| Fan, HX; Fang, H; Huang, H; Li, XS; Song, YL; Zhou, CW | 1 |
| Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Chang, JW; Chen, CH; Lin, CM; Tsao, TC | 1 |
| de Vries, EG; Groen, HJ; Maring, JG; Maurer, M; Uges, DR; Wachters, FM | 1 |
| Cegovnik, U; Kern, I; Korošec, P; Košnik, M; Rijavec, M; Silar, M; Triller, N | 1 |
| Chen, Y; Li, H; Liu, DZ; Yan, D; Zeng, HY; Zhou, CW | 1 |
| Xiao, QM; Zhang, WD; Zhou, JH | 1 |
| Boezen, HM; de Leede, GP; de Vries, EG; Eppinga, P; Erjavec, Z; Groen, HJ; Kramer, H; Strijbos, JH; Van Putten, JW; Wachters, FM | 1 |
| Chen, MC; Cheng, AL; Hsu, CH; Whang-Peng, J; Yang, CH; Yang, PC; Yeh, KH; Yu, YC | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Battiloro, C; Caponigro, F; Danilo, R; Formato, R; Iaffaioli, RV; Illiano, A; Tortoriello, A | 1 |
| Biesma, B; Bolhuis, RJ; Paul, MA; Phernambucq, EC; Postmus, PE; Schramel, FM; Smit, EF; vd Tol, A | 1 |
| Chang, LC; Kuo, KW; Liang, CH; Sheu, HM; Shiu, LY | 1 |
| Argnani, M; Ciucci, G; De Giorgi, U; Kopf, B; Marangolo, M; Minzi, C; Rosti, G | 1 |
| Cheng, AL; Hsu, C; Hu, FC; Huang, TC; Kuo, SH; Lin, CC; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Abad, A; Ariza, A; Barnadas, A; Carles, J; Fernandez-Vasalo, G; Pellicer, I; Rosell, R; Sanchez, JJ | 1 |
| Airoma, G; Bianco, AR; De Placido, S; Gridelli, C; Incoronato, P; Palazzolo, G; Pepe, R; Rossi, A | 1 |
| Anania, C; Casaretti, R; Comella, G; Comella, P; Curcio, C; Daponte, A; Maiorino, A; Musetta, G; Scoppa, G | 1 |
| Feld, R | 1 |
| Chasen, M; De Caro, L; Dhingra, H; Fossella, F; Komaki, R; Lee, JS; McGavran, M; Putnam, JB; Roth, JA; Ryan, MB | 1 |
| Antilli, A; Ardizzoni, A; Bruzzi, P; De Marinis, F; Mariani, GL; Pallotta, G; Pennucci, MC; Rosso, R; Rubagotti, A; Salvati, F | 1 |
| Funasako, M; Kobayashi, H; Nishio, K; Nishio, M; Ohata, M; Saijo, N; Sasaki, Y; Suruda, T; Uetani, K | 1 |
| Bakker, M; Groen, HJ; Postmus, PE; Riggi, M; Smeets, J; Smit, EF | 1 |
| Bianco, AR; Bruni, GS; Gridelli, C; Incoronato, P; Rinaldi, L; Rossi, A; Ruffolo, P; Scognamiglio, F | 1 |
| Arriagada, R; Le Chevalier, T; Le Péchoux, C | 1 |
| Brancaccio, L; Carnicelli, P; Cioffi, R; Comella, P; De Cataldis, G; Ianniello, GP; Lombardi, A; Maiorino, A; Scarpati, MD; Tinessa, V | 1 |
| Brugger, W; Engelhardt, R; Fetscher, S; Frommhold, H; Hasse, J; Kanz, L; Lange, W; Mertelsmann, R; Wenger, M | 1 |
| Cariello, S; Colucci, G; Galetta, D; Gebbia, N; Gebbia, V; Riccardi, F | 1 |
| Chen, YM; Lin, WC; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW; Wu, MF | 1 |
| Ambrosini, G; Busutti, L; Caffo, O; Farris, A; Ferrara, G; Guaraldi, M; Lelli, G; Martoni, A; Palomba, G; Pannuti, F; Petralia, A; Piana, E; Picece, V; Preti, P; Raimondi, M; Recaldin, E; Robustelli, G; Sarobba, G; Strocchi, E | 1 |
| Bianco, A; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Natale, M; Nicolella, G; Pacilio, C; Panza, N | 1 |
| Drag-Zalesińska, M; Gebarowska, E; Wysocka, T; Zabel, M | 1 |
| Gebarowska, E; Kołodziej, J; Majewski, A; Zabel, M | 1 |
| Brugger, W; Engelhardt, R; Fetscher, S; Frommhold, H; Hasse, J; Kanz, L; Lange, W; Mertelsmann, R | 1 |
| Chang, WJ; Chen, CH; Liaw, CC; Tsao, TC; Yang, CT | 1 |
| Guaraldi, M; Martoni, A; Piana, E | 1 |
| Chen, YM; Lin, WC; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW; Yang, KY | 1 |
| Comte-Bardonnet, M; Daurès, JP; Khial, F; Marcillac, I; Oliver, P; Pujol, JL; Quantin, X; Rivière, A | 1 |
| Ceresoli, GL; Dell'Oro, S; Passoni, P; Villa, E | 1 |
| Chen, Y; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW; Yang, KY | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Biesma, B; Giaccone, G; Huisman, C; Postmus, PE; Schramel, FM; Smit, EF | 1 |
| Canessa, P; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Van Putten, JW | 1 |
| Yao, H; Zhou, J; Zhu, Q | 1 |
| Chu, DT; Li, JL; Qu, FL; Sun, Y; Zhang, XR | 1 |
| Bielawski, K; Falkiewicz, B; Granetzny, A; Klinke, F; Vogt, U; Zaczek, A | 1 |
| Evans, WK; Feld, R; Gupta, S; Lassus, M; Shannon, P; Shepherd, FA; Walde, PL; Wierzbicki, R | 1 |
| Berendsen, HH; Piers, DA; Postmus, PE; Riva, A; Smeets, J; Smit, EF | 1 |
| Airoma, G; Bianco, AR; Gridelli, C; Incoronato, P; Palazzolo, G; Pepe, R; Rossi, A | 1 |
| Thongprasert, S | 1 |
| Piers, DA; Postmus, PE; Smit, EF | 1 |
| Busutti, L; Casadio, M; Guaraldi, M; Martoni, A; Pannuti, F | 1 |
| Beltrami, V; Bianco, AR; Ferrante, G; Gentile, M; Gridelli, C; Iacobelli, S; Irtelli, L; Martino, T; Natoli, C; Rossi, A | 1 |
| Balli, M; Bonciarelli, G; Jirillo, A; Lonardi, F; Pavanato, G | 1 |
| Biscottini, B; Cellerino, R; Fatati, G; Guidi, F; Isidori, P; Raspugli, M; Tummarello, D | 1 |
| Guaraldi, M; Martoni, A; Melotti, B; Pannuti, F | 1 |
| Kajanti, M; Mattson, K; Niiranen, A; Pyrhönen, S | 1 |
| Guaraldi, M; Martoni, A; Melotti, B; Pacciarini, MA; Pannuti, F; Riva, A | 1 |
| Riva, A; Sala, L; Smeets, J; Utama, I; Wils, J | 1 |
| Bonardi, G; Calciati, A; Donadio, M; Giaccone, G; Iberti, V | 1 |
| Balli, M; Bonciarelli, G; Demicheli, R; Jirillo, A; Lonardi, F | 1 |
| Adamo, V; Alafaci, E; Altavilla, G; Buemi, B; Caristi, N; Condemi, G; Toscano, G | 1 |
| Arai, R; Fukuoka, M; Furuse, K; Kawahara, M; Kodama, N; Matsui, K; Negoro, S; Ryu, S; Takada, M; Yamamoto, M | 1 |
| Smeets, J; Utama, I; Wils, J | 1 |
| Biscottini, B; Cellerino, R; Fatati, G; Guidi, F; Isidori, P; Porfiri, E; Raspugli, M; Tummarello, D | 1 |
| Casadio, M; Giordani, S; Giuliotti, C; Lelli, G; Martoni, A; Pannuti, F; Strocchi, E | 1 |
| Abad-Esteve, A; Fernandez, C; Monras, P; Moreno, I; Morera, J; Ribas-Mundo, M; Rosell, R; Ruiz, J | 1 |
4 review(s) available for epirubicin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
High-dose or dose-intensive chemotherapy for non-small cell carcinoma of the lung.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Humans; Lung Neoplasms | 1994 |
Anthracyclines in non-small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Epirubicin; Humans; Lung Neoplasms | 2001 |
The treatment of advanced non-small-cell lung cancer (NSCLC)--overseas updated and local experiences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Epirubicin; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Survival Rate | 2002 |
42 trial(s) available for epirubicin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Value of whole-tumor dual-input perfusion CT in predicting the effect of multiarterial infusion chemotherapy on advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Perfusion Imaging; Radiography, Thoracic; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Induction Chemotherapy; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2016 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2009 |
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2005 |
Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2006 |
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Pneumonectomy; Survival Analysis | 2006 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 1993 |
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1994 |
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Statistics as Topic; Survival Analysis; Time Factors; Treatment Outcome | 1994 |
Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Italy; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia | 1993 |
Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1993 |
Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vinblastine; Vinorelbine | 1995 |
Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1996 |
Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vindesine | 1996 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Lung Neoplasms; Male; Middle Aged; Palliative Care; Pneumonectomy; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 1997 |
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Vinblastine; Vinorelbine | 1997 |
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Epirubicin; Female; Fluorouracil; Humans; Ifosfamide; Leucovorin; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Salvage Therapy | 1998 |
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Vinblastine; Vindesine; Vinorelbine | 1999 |
[Epirubicin containing regimens in advanced malignant tumors report of 516 cases. Epirubicin Collaborative Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Vincristine | 1997 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Survival Rate | 1999 |
Anthracyclines in non-small-cell lung cancer: do they have a therapeutic role?
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Tamoxifen | 2000 |
Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Treatment Outcome | 2000 |
Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Ventricular Fibrillation | 2000 |
Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Epirubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis; Taiwan; Tamoxifen; Treatment Outcome | 2000 |
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2001 |
Activity of the combination of high-dose epirubicin with gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Heart Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epirubicin; Female; Hemoglobins; Humans; Infusions, Intravenous; Leukocyte Count; Leukopenia; Lung Neoplasms; Male; Middle Aged; Platelet Count; Ventricular Function, Left | 1992 |
Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Epirubicin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1992 |
A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1992 |
A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prognosis; Radiotherapy; Survival Rate | 1991 |
Activity of high-dose epirubicin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Evaluation; Epirubicin; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Stroke Volume | 1991 |
Epirubicin in patients with inoperable non-small cell lung cancer--a phase II study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1991 |
4'-EPI-doxorubicin in advanced lung cancer. A phase II trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Evaluation; Drugs, Investigational; Epirubicin; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged | 1990 |
Bleomycin, vincristine, mitomycin and cisplatin alternated with cyclophosphamide, 4'-epidoxorubicin and procarbazine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Procarbazine; Vincristine | 1988 |
Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Prospective Studies; Random Allocation | 1988 |
A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4'-epidoxorubicin, and VP-16 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Podophyllotoxin; Random Allocation | 1987 |
31 other study(ies) available for epirubicin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The effects of epirubicin-loaded Boc-L-Diphenylalanine peptide nanoparticles on cytotoxicity, genotoxicity, oxidative stress, and apoptosis in non-small cell lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dipeptides; DNA Damage; Epirubicin; Humans; Lung Neoplasms; Nanoparticles; Oxidative Stress | 2023 |
RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Diosgenin; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Rats; Xenograft Model Antitumor Assays | 2020 |
Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epirubicin; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Receptors, Notch; Terfenadine; Tumor Burden; Wound Healing | 2017 |
Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antigens, CD; Cadherins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Epirubicin; Humans; Liposomes; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Xenograft Model Antitumor Assays | 2017 |
Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epirubicin; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Janus Kinase 2; Lung Neoplasms; MicroRNAs; Phosphoric Monoester Hydrolases; STAT3 Transcription Factor | 2018 |
Development of R
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Drug Liberation; Epirubicin; Humans; Lipid Bilayers; Liposomes; Lung Neoplasms; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2019 |
Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Saliva | 2010 |
Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2011 |
[Evaluation of the efficacy of bronchial arterial infusion chemotherapy for the treatment of central non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Epirubicin; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Survival Rate | 2011 |
[Clinical efficacy of the combination chemotherapy of high-dose epirubicin in non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin | 2001 |
Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Epirubicin; fas Receptor; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Poly-ADP-Ribose Binding Proteins; RNA, Messenger; Solanaceous Alkaloids; Up-Regulation | 2007 |
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukapheresis; Lung Neoplasms; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins | 2007 |
Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CD57 Antigens; Cell Differentiation; Chromogranin A; Chromogranins; Cisplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Ifosfamide; Immunologic Factors; Interferons; Karnofsky Performance Status; Life Tables; Lung Neoplasms; Male; Middle Aged; Mitomycin; Multivariate Analysis; Neoplasm Proteins; Neoplasm Staging; Phosphopyruvate Hydratase; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Rate; Synaptophysin; Vindesine | 1993 |
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Humans; Lung Neoplasms | 1995 |
Evaluation of apoptosis and necrosis induction in cultured cells of lung carcinomas under effect of cytostatic drugs in vitro.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Etoposide; Humans; Lung Neoplasms; Methotrexate; Necrosis; Tumor Cells, Cultured; Vinblastine; Vincristine | 1999 |
Evaluation of individual sensitivity to cytostatic drugs of in vitro cultured lung tumor cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Epirubicin; Etoposide; Fluorouracil; Lung Neoplasms; Methotrexate; Tumor Cells, Cultured; Vinblastine; Vincristine | 1999 |
The effects of two different cisplatin-based chemotherapy regimens on advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 1999 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
[Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; fas Receptor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitric Oxide; Teniposide; Treatment Outcome | 2000 |
p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; DNA Mutational Analysis; DNA, Complementary; DNA, Neoplasm; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Genes, p53; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Tumor Cells, Cultured | 2002 |
Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Vindesine | 1992 |
Analysis of the four combination chemotherapies in non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycin; Survival Rate; Vinblastine | 1992 |
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Treatment Outcome | 1992 |
The role of three cisplatin-based chemotherapy regimens in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies; Vincristine; Vindesine | 1992 |
High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms | 1990 |
Phase II study of high-dose epirubicin in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1990 |
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Procarbazine | 1989 |
[Phase II studies of a single agent and a cis-platinum-based two-drug combination in patients with non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis | 1988 |
Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1988 |
Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |